| Optimized 2D-RT for Prostate Cancer (NCT03339531) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2015-02-02 |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients (NCT02376296) | Saladax Biomedical, Inc. | 2015-02-01 |
| Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02344017) | Orion Corporation, Orion Pharma | 2015-02-01 |
| Study Comparing MRI/Ultrasound Fusion-guided Prostate Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy (NCT02450266) | Heinrich-Heine University, Duesseldorf | 2015-02-01 |
| Xbox Kinect Training in Men With Prostate Cancer (NCT01762241) | Hospitalsenheden Vest | 2015-02-01 |
| Irish Programme for Stratified Prostate Cancer Therapy (NCT03162003) | Cancer Trials Ireland | 2015-02-01 |
| Geriatric Determinants of General Repercussion of Radiotherapy for Patient Over 75 Years With Prostate Cancer (NCT02876237) | Institut Cancerologie de l'Ouest | 2015-02-01 |
| PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy (NCT02131649) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2015-02-01 |
| Utilizing MRI to Study the Effect of Sulforaphane on Prostate Cancer (NCT02404428) | Quadram Institute Bioscience | 2015-02-01 |
| A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (NCT02203513) | National Cancer Institute (NCI) | 2015-01-20 |
| Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer (NCT02349139) | Asana BioSciences | 2015-01-19 |
| Observational Study of Patients Who Underwent Diagnostic Investigation (Prostate Biopsy) and/or Radical Prostatectomy Surgery. (NCT06397755) | IRCCS San Raffaele | 2015-01-08 |
| Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer (NCT02339701) | Chinese University of Hong Kong | 2015-01-07 |
| Olive Oil v Prostate Cancer Foundation Diet for Treatment of Prostate Cancer (NCT03084913) | The Miriam Hospital | 2015-01-01 |
| Localising Occult Prostate Cancer Metastases With Advanced Imaging TEchniques (NCT02935816) | University College, London | 2015-01-01 |
| Evaluation of a Web-based Decision Aid Tool for Prostate Cancer Patients (NCT03278197) | Maastricht Radiation Oncology | 2015-01-01 |
| Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma (NCT03284151) | Centre Francois Baclesse, Luxembourg | 2015-01-01 |
| Study of ES414 in Metastatic Castration-Resistant Prostate Cancer (NCT02262910) | Aptevo Therapeutics | 2015-01-01 |
| C-arm Cone-beam CT in Prostate Brachytherapy (NCT02322931) | British Columbia Cancer Agency | 2015-01-01 |
| Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients (NCT02303327) | Sir Mortimer B. Davis - Jewish General Hospital | 2015-01-01 |
| Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy (NCT02349022) | ImaginAb, Inc. | 2015-01-01 |
| Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer (NCT02375035) | Cambridge University Hospitals NHS Foundation Trust | 2015-01-01 |
| Focal Prostate Radio-Frequency Ablation (NCT02328807) | H. Lee Moffitt Cancer Center and Research Institute | 2014-12-29 |
| Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer (NCT02410044) | iOMEDICO AG | 2014-12-23 |
| Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer (NCT02279693) | Centre Georges Francois Leclerc | 2014-12-22 |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) (NCT02319837) | Pfizer | 2014-12-17 |
| Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers (NCT03908684) | Sunnybrook Health Sciences Centre | 2014-12-17 |
| Repeatability of Positron Emission Tomography (TEP) With fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium (NCT03105869) | Poitiers University Hospital | 2014-12-16 |
| CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC. (NCT03381326) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2014-12-15 |
| Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer (NCT02425228) | Jonsson Comprehensive Cancer Center | 2014-12-04 |
| Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (NCT02279862) | Bristol-Myers Squibb | 2014-12-02 |
| Intensity-modulated Radiation Therapy From 70Gy to 80Gy in Localized Prostate Cancer (NCT02974231) | Institut de Cancérologie de Lorraine | 2014-12-01 |
| Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer (NCT02334579) | Swedish Medical Center | 2014-12-01 |
| Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid (NCT02274623) | OPKO Health, Inc. | 2014-12-01 |
| Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2 (NCT02229734) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2014-12-01 |
| Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma (NCT02264379) | Technische Universität Dresden | 2014-12-01 |
| Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy (NCT02312401) | Memorial Sloan Kettering Cancer Center | 2014-12-01 |
| Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer (NCT02745496) | University of Dundee | 2014-12-01 |
| MRI Based Active Selection for Treatment Trial (NCT02242773) | University of Miami | 2014-11-12 |
| Structural Network on Prostate Cancer in the French Greater West Region (NCT03214315) | University Hospital, Tours | 2014-11-11 |
| Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer (NCT02353832) | University of Texas Southwestern Medical Center | 2014-11-06 |
| Physical Activity Intervention in African American Men After Radical Prostatectomy (NCT02621684) | Washington University School of Medicine | 2014-11-01 |
| Registry to Measure the Impact of Adding Genomic Testing (NCT02454595) | Myriad Genetic Laboratories, Inc. | 2014-11-01 |
| Laparoscopic vs Robotic-Assisted Radical Prostatectomy (NCT03682146) | University of Leipzig | 2014-11-01 |
| Pilot Study of SBRT and CDX-1127 in Prostate Cancer (NCT02284971) | James Larner, MD | 2014-11-01 |
| Cancer DNA Detection in Blood and Urine (NCT02657863) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-11-01 |
| Evaluation of the Practice of the TEP Choline at Patients With Prostate Cancer (NCT03201380) | Institut Paoli-Calmettes | 2014-11-01 |
| [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer (NCT02297386) | Memorial Sloan Kettering Cancer Center | 2014-11-01 |
| MR-targeted vs. Random TRUS-guided Prostate Biopsy (NCT02678481) | Fondazione del Piemonte per l'Oncologia | 2014-11-01 |
| Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer (NCT02290366) | Ronald M. Benoit, MD | 2014-11-01 |
| Choline PET/CT vs. Dual Time Point FDG PET/CT in Prostate Cancer (NCT02232724) | Odense University Hospital | 2014-11-01 |
| Molecular Mechanisms Underlying Prostate Cancer Disparities (NCT02229565) | Duke University | 2014-11-01 |
| A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer (NCT02293707) | Laboratoires Leurquin Mediolanum | 2014-11-01 |
| Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device (NCT02255890) | Clinical Research Office of the Endourological Society | 2014-11-01 |
| Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer (NCT02280356) | Memorial Sloan Kettering Cancer Center | 2014-10-28 |
| Genetic Evaluation of Men (GEM) (NCT03076242) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-10-23 |
| Exercise, Prostate Cancer and Circulating Tumour Cells (NCT02453139) | University of Dublin, Trinity College | 2014-10-01 |
| MRI in Active Surveillance of Prostate Cancer (NCT02326246) | Aarhus University Hospital Skejby | 2014-10-01 |
| To Evaluate the Effect of MCS® in Prostate Cancer Prevention (NCT02042807) | Health Ever Bio-Tech Co., Ltd. | 2014-10-01 |
| Energy Balance for Prostate Cancer Survivorship (NCT02252484) | Jill Hamilton-Reeves, PhD RD LD | 2014-10-01 |
| Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer (NCT02125084) | SCRI Development Innovations, LLC | 2014-10-01 |
| Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound (NCT02225925) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-10-01 |
| Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer (NCT02342054) | Hospital de Cruces | 2014-10-01 |
| CyberKnife for Prostate Cancer Patients Aged 70 y or More (NCT03235557) | Centre Francois Baclesse, Luxembourg | 2014-10-01 |
| AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT02420587) | M.D. Anderson Cancer Center | 2014-10-01 |
| Digital Rectal Exam Proficiency Tool (NCT02278679) | University of Virginia | 2014-10-01 |
| 18-F-Fluoroacetate as PET Imaging Agent (NCT01320787) | M.D. Anderson Cancer Center | 2014-10-01 |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate (NCT02268175) | Dana-Farber Cancer Institute | 2014-10-01 |
| WB-DW-MRI vs CHOLINE-PET/CT for Selecting Treatments in Recurrent Prostate Cancer (NCT02858128) | Hospital Provincial de Castellon | 2014-10-01 |
| Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial (NCT02391051) | University of Erlangen-Nürnberg Medical School | 2014-10-01 |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer (NCT02064608) | Cambridge University Hospitals NHS Foundation Trust | 2014-10-01 |
| A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy (NCT02124668) | Astellas Pharma Europe B.V. | 2014-09-23 |
| Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer (NCT01990196) | Jonsson Comprehensive Cancer Center | 2014-09-23 |
| Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases (NCT02135484) | M.D. Anderson Cancer Center | 2014-09-19 |
| Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer (NCT02224911) | Jonsson Comprehensive Cancer Center | 2014-09-11 |
| Intra-operative Neuromodulation of the Pelvic Plexus (NCT03425240) | Laikο General Hospital, Athens | 2014-09-10 |
| MRI Before Biopsy in Diagnosing Patients With Prostate Cancer (NCT02131207) | Case Comprehensive Cancer Center | 2014-09-10 |
| Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry (NCT02282644) | Hospices Civils de Lyon | 2014-09-08 |
| Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors (NCT02321358) | Memorial University of Newfoundland | 2014-09-01 |
| Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. (NCT02213107) | University of Rochester | 2014-09-01 |
| Timing of HDR With EBRT in Localised Prostate Cancer,Toxicity and Quality of Life Assessment (NCT02618161) | Mid and South Essex NHS Foundation Trust | 2014-09-01 |
| A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy (NCT02159690) | Kenneth Pienta, MD | 2014-09-01 |
| PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study (NCT02250313) | MDx Health | 2014-09-01 |
| Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer (NCT02212197) | Camurus AB | 2014-09-01 |
| Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors (NCT02233842) | National Cancer Institute (NCI) | 2014-09-01 |
| Prostate Hypoxia - TIC (NCT02095249) | University Health Network, Toronto | 2014-09-01 |
| MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer (NCT02303054) | NYU Langone Health | 2014-09-01 |
| Whole Body Bone Scan vs 18F-Choline PET/CT in Prostate Cancer (NCT02232685) | Odense University Hospital | 2014-09-01 |
| An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy (NCT02248350) | Georgetown University | 2014-09-01 |
| 18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer (NCT02121600) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2014-09-01 |
| Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations (NCT02705846) | Institute of Cancer Research, United Kingdom | 2014-09-01 |
| Prostate Cancer Genomic Heterogeneity (NCT02022371) | University College London Hospitals | 2014-09-01 |
| Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation (NCT03297385) | The Netherlands Cancer Institute | 2014-08-28 |
| RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) (NCT02090114) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-08-25 |
| Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (NCT02274779) | Institut Cancerologie de l'Ouest | 2014-08-20 |
| T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer (NCT02113657) | M.D. Anderson Cancer Center | 2014-08-20 |
| Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents (NCT02053311) | Swiss Cancer Institute | 2014-08-19 |
| Perioperative Post-Prostatectomy Incontinence Home Telehealth Program (NCT01960998) | VA Office of Research and Development | 2014-08-11 |
| Prostate Cancer Upgrading Reference Set (NCT02189486) | The University of Texas Health Science Center at San Antonio | 2014-08-01 |
| Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy (NCT02138760) | Kaiser Permanente | 2014-08-01 |